QuantX Biosciences closed an oversubscribed $85M Series B financing.
- Amount
- $85M
- Stage
- Series B
- Announced
- 9 February 2026
- Leads
- LAV, Sanofi Ventures
- Other investors
- Hongshan
- Use of funds
- Clinical development of STAT6 and IL-17 oral small molecule inhibitors, plus continued discovery efforts in immunology and inflammation.
- Total raised
- $130M to date
- Checked
- Amount and date checked against the press source